4:30 PM
 | 
Sep 06, 2018
 |  BioCentury  |  Finance

Evox populates its pipeline

Why exosome therapeutics play Evox is focusing first on rare diseases

As Evox Therapeutics Ltd. continues to refine the platform with which it develops exosome-based therapeutics, the company plans to use its £35.5 million ($45.9 million) series B round to start clinical trials on as many as three rare disease therapies in its pipeline.

Oxford, U.K.-based Evox is developing exosome therapies that use specially engineered versions of the extracellular vesicles to ferry therapeutic cargoes to specific tissues, cell types or other areas of interest that are otherwise difficult to reach with drugs. The payloads can include proteins, nucleic acids, antibodies or small molecules.

Funded originally by Oxford Sciences Innovation (OSI), which was the lone investor in Evox’s £10 million series A round, the company raised the series B from an international syndicate. Evox’s new investors include U.S.-based Redmile Group, GV, Cowen Healthcare Investments...

Read the full 636 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >